Jade Biosciences, Inc. (JBIO)
16.57
+0.17
(+1.04%)
USD |
NASDAQ |
Nov 11, 16:00
16.57
0.00 (0.00%)
After-Hours: 17:33
Jade Biosciences Shareholders Equity (Quarterly) : 439.92M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 439.92M |
| March 31, 2026 | 296.46M |
| December 31, 2025 | 332.52M |
| September 30, 2025 | 179.35M |
| June 30, 2025 | 201.56M |
| March 31, 2025 | 75.05M |
| December 31, 2024 | 76.43M |
| September 30, 2024 | 80.49M |
| June 30, 2024 | 94.40M |
| March 31, 2024 | 90.90M |
| December 31, 2023 | 109.46M |
| September 30, 2023 | 125.72M |
| Date | Value |
|---|---|
| June 30, 2023 | 141.93M |
| March 31, 2023 | 113.10M |
| December 31, 2022 | 126.74M |
| September 30, 2022 | 139.14M |
| June 30, 2022 | 151.05M |
| March 31, 2022 | 161.95M |
| December 31, 2021 | 172.42M |
| September 30, 2021 | 179.85M |
| June 30, 2021 | 58.24M |
| March 31, 2021 | 8.166M |
| December 31, 2020 | 2.941M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.387B |
| Alnylam Pharmaceuticals, Inc. | 3.604B |
| Anika Therapeutics, Inc. | 137.58M |
| Savara, Inc. | 107.85M |
| Vericel Corp. | 384.17M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 472.11M |
| Total Liabilities (Quarterly) | 32.20M |
| Debt to Equity Ratio | 0.0014 |
| Current Ratio | 14.93 |
| Net Debt Paydown Yield | 0.00% |